Bifogade filer
BrainCool AB (publ): BrainCool receives a patent approval for "shivering" in the EU for the product BrainCool™ System
Kurs
+0,89%
Likviditet
3,03 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-11 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-03 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-15 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-13 | N/A | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2025-05-12 | N/A | Årsstämma |
| 2025-05-02 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-11 | - | Bokslutskommuniké 2024 |
| 2024-11-01 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-26 | - | Årsstämma |
| 2024-04-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2024-04-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2023-11-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2023-02-15 | - | Extra Bolagsstämma 2022 |
| 2022-11-30 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-31 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-02-28 | - | Bokslutskommuniké 2021 |
| 2021-11-30 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-31 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-16 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2021-04-15 | - | Årsstämma |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-27 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2020-06-30 | - | Årsstämma |
| 2020-05-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-17 | - | Årsstämma |
| 2019-04-08 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
| 2018-07-25 | - | Extra Bolagsstämma 2018 |
| 2018-05-09 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-19 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2018-04-18 | - | Årsstämma |
| 2018-02-16 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-29 | - | Årsstämma |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-24 | - | Extra Bolagsstämma 2017 |
| 2017-04-12 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2017-02-14 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-14 | - | Årsstämma |
| 2016-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2016-01-28 | - | Bokslutskommuniké 2015 |
| 2015-10-22 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-27 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2015-03-26 | - | Årsstämma |
| 2015-01-27 | - | Bokslutskommuniké 2014 |
| 2014-10-20 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-19 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-26 | - | X-dag ordinarie utdelning BRAIN 0.00 SEK |
| 2014-06-25 | - | Årsstämma |
| 2014-04-14 | - | Extra Bolagsstämma 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The final step for patent protection of the BrainCool™ System has been completed with the approval of our technology to manage shivering during cooling in the EU. The patent for addressing 'shivering' has already been approved in the USA, Sweden, Japan, South Korea, and China.
CEO Martin Waleij comments:
-"It is a clear and significant indication of the level of technology and degree of innovation of the product, which ensures its special position as a leading 'high-quality TTM system' globally.
Our patented product, the BrainCool™ System, is designed to accommodate various treatment strategies, target temperatures, and indications. The system has the capability to achieve rapid and strong cooling effects, and its patented features offer significant advantages over competing products.”
Contacts
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se
About Us
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology.
BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.